Mellalta Meets

Mellalta Meets conducted a Competitive Landscape & Competitive Intelligence study on the G7 Acute Myeloid Leukemia market. The research aimed to analyze market dynamics, treatment trends, disruptive events, and critical opportunities

This TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc)

Mellalta Meets conducted a survey in the United States to understand doctors' and KOL's concerns and opinion regarding the impact of recent ACIP guidelines on Pneumococcal Vaccine prescriptions (Prevnar 13 and Pneumovax 23) What is answered! • Changing...

Market adoption of gene therapy in haemophilia A is still a cause for concern due to the expected high prices, durability issues, redosing, safety concerns and key unknown factors that are still under discussion.

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company, with an impressive Antibody Warhead Enabling (AWE) technology.

Karyopharm's Selinexor (Xpovio) an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval.

Daiichi Sankyo unveiled about the collaboration between them and AstraZeneca for antibody drug conjugate, DS-1062. This news has created absolute havoc in the Pharma market.

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge.

Cabaletta and Artisan bio enter into a gene research collaboration.

Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the phase 1 study of mitapivat (AG-348) in patients with sickle cell anemia.